The four awards include: "Securing multiple contract modifications with the U.S. government for our medical countermeasure products affirms that Emergent is a trusted biodefense partner, and also demonstrates the strength and sustainment of our product portfolio," said Paul Williams, senior vice president, products head at Emergent. "As part of our longstanding public-private partnership, we stand ready to continue fulfilling preparedness priorities and stockpiling efforts in the U.S. and abroad." Indicatio ...

"The decision to sell our Camden manufacturing facility is aligned with our multi-year plan to create a customer focused, leaner and more flexible organization, while we improve overall profitability and raise capital to reduce our debt," said Joe Papa, President and CEO at Emergent. "We are grateful to our dedicated colleagues who have embodied Emergent's mission to protect and enhance life by delivering on our customers' commitments. We are working to ensure a smooth transition to Bora, especially for our ...

While recent data from the Centers for Disease Control and Prevention (CDC) found a first annual decrease in opioid-related deaths since 2018 in the U.S., fentanyl poisonings are still on the rise and over 100,000 lives were still lost to preventable opioid overdose death in 2023.2 Williams added, "In addition to working with critical public interest groups and broadening consumer access in the OTC retail setting, Emergent is also engaging with partners who are aligned with our mission to expand access, awa ...

Naloxone is a medication that rapidly reverses the effects of opioid overdose and is the standard of care for opioid overdose reversal in a community setting New topline survey findings reinforce the need for continued education on naloxone While recent data from the Centers for Disease Control and Prevention (CDC) found a first annual decrease in opioid-related deaths since 2018 in the U.S., fentanyl poisonings are still on the rise and over 100,000 lives were still lost to preventable opioid overdose deat ...

GAITHERSBURG, Md., May 10, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that its 2024 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 23, 2024 at 9:00 am eastern time. HOW TO PARTICIPATE IN THE VIRTUAL ANNUAL MEETINGAs described in the annual proxy statement, stockholders of record are eligible to participate in and ask questions during the Virtual Annual Meeting. Visit this webpage and enter the 16-digit Control ...

Emergent BioSolutions (NYSE:EBS) layoffs are in the news as the life sciences company prepares to cut jobs and close down certain facilities.According to a release from Emergent BioSolutions, these layoffs will affect 300 of its employees. The company also says that it will be closing 85 open positions that are currently vacant.The job cuts will also see Emergent BioSolutions close down two of its locations. That includes its Baltimore-Bayview Drug Substance manufacturing facility and Rockville, Maryland Dr ...

Emergent BioSolutions Inc. (NYSE:EBS) Q1 2024 Earnings Call Transcript May 1, 2024 5:00 PM ET Company Participants Joe Papa - President and CEO Rich Lindahl - EVP and CFO Paul Williams - SVP, Products Business Operator Good afternoon, everyone. I'm the operator for today's call. Thank you for joining today as Emergent discusses their operational and financial results for the first quarter of 2024. As is customary, today's call is open to all participants, and the call is being recorded and is copyrighted by ...

| --- | --- | |-----------|-------| | | | | | | | | | | | | | Q1 2024 | | | Financial | | | Results | | | Update | | | | | | | | | | | | | | | | | | May 1, 2024 | | | | | | | | | | | | | | | | | | | | 1 PROPRIETARY AND CONFIDENTIAL 2 Q1 2024 Update Introduction INTRODUCTION Safe Harbor Statement/Trademarks | --- | --- | --- | |-------|-------|-------| | Presenter \nJoseph C. Papa | • | Topic(s) \nTransformation Plan Update | | President and CEO | | | | Rich Lindahl | • | Q1 2024 Financial Review | | EVP, CF ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33137 EMERGENT BIOSOLUTIONS INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 14-1902018 (State or Other Jurisdiction o ...

EMERGENT BIOSOLUTIONS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS • First Quarter 2024 Total Revenues of $300.4 million, above the prior guidance range • First Quarter 2024 Net Income of $9.0 million and Adjusted EBITDA of $66.9 million • Updates FY 2024 guidance GAITHERSBURG, Md., May 1, 2024—Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the first quarter ended March 31, 2024. "We delivered a strong quarter with growth across all our key products,” said Joe Papa, President an ...